Metabolic and inflammatory profile in obese patients with chronic obstructive pulmonary disease

Chronic Respiratory Disease

Volumn 5, Issue 1, 2008, Pages 35-41

  Poulain, M ^a,b,c   Doucet, M ^b   Drapeau, V ^c   Fournier, G ^c   Tremblay, A ^c   Poirier, P ^b   Maltais, F ^b  

^a Clinique du Souffle La Solane   (France)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

Author keywords

Cardiovascular diseases; COPD; Diabetes; Inflammation; Metabolic syndrome; Obesity

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LEPTIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; AIRWAY OBSTRUCTION; ANTHROPOMETRY; ARTICLE; BLOOD PRESSURE; BODY COMPOSITION; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; LIPOPROTEIN BLOOD LEVEL; LUNG FUNCTION; MALE; METABOLIC SYNDROME X; OBESITY; PREVALENCE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 46149108589     PISSN: 14799723     EISSN: 14799731     Source Type: Journal    
DOI: 10.1177/1479972307087205     Document Type: Article

References (34)

1. Wilson DO, Rogers RM, Wright EC, Anthonisen NR Body weight in chronic obstructive pulmonary disease. The National Institutes of Health Intermittent Positive-Pressure Breathing Trial. Am Rev Respir Dis 1989 ; 139: 1435 - 8.
2. Schols AM, Slangen J., Volovics L., Wouters EF Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998 ; 157: 1791 - 7.
3. Marquis K., Debigaré R., Lacasse Y. et al. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002 ; 166: 809 - 13.
4. Celli BR, Cote CG, Marin JM et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004 ; 350: 1005 - 12.
5. Landbo C., Prescott E., Lange P., Vestbo J., Almdal TP Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999 ; 160: 1856 - 61.
6. Vestbo J., Prescott E., Almdal T. et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med 2006 ; 173: 79 - 83.
7. Curtis JP, Selter JG, Wang Y. et al. The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med 2005 ; 165: 55 - 61.
8. Poirier P., Giles TD, Bray GA et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006 ; 113: 898 - 918.
9. Isomaa B., Almgren P., Tuomi T. et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001 ; 24: 683 - 9.
10. Lakka HM, Lakka TA, Tuomilehto J., Salonen JT Abdominal obesity is associated with increased risk of acute coronary events in men. Eur Heart J 2002 ; 23: 706 - 13.
11. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006 ; 444: 881 - 7.
12. Sin DD, Man SF Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003 ; 107: 1514 - 9.
13. Marquis K., Maltais F., Duguay V. et al. The metabolic syndrome in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil 2005 ; 25: 226 - 32.
14. Ford ES, Giles WH, Dietz WH Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002 ; 287: 356 - 9.
15. Bolton CE, Evans M., Ionescu AA et al. Insulin resistance and inflammation - A further systemic complication of COPD. COPD 2007 ; 4: 121 - 6.
16. Miller MR, Hankinson J., Brusasco V. et al. Standardisation of spirometry. Eur Respir J 2005 ; 26: 319 - 8.
17. Wanger J., Clausen JL, Coates A. et al. Standardisation of the measurement of lung volumes. Eur Respir J 2005 ; 26: 511 - 22.
18. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R., Yernault JC Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993 ; 16: 5 - 40.
19. Rabe KF, Hurd S., Anzueto A. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007 ; 176: 532 - 55.
20. Lohmann T., Roche A.R.M. The Airlie (VA) consensus: standardization of anthropometric measurements. Human Kinetic Publishers, Champaign IL, 1988: 39 - 80.
21. Friedewald WT, Levy RI, Fredrickson DS Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972 ; 18: 499 - 502.
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 ; 28: 412 - 9.
23. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001 ; 285: 2486 - 97.
24. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005 ; 112: 2735 - 52.
25. Schols AM, Broekhuizen R., Weling-Scheepers CA, Wouters EF Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr 2005 ; 82: 53 - 9.
26. Anthonisen NR, Skeans MA, Wise RA, Manfreda J., Kanner RE, Connett JE The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005 ; 142: 233 - 9.
27. Hole DJ, Watt GC, Davey-Smith G., Hart CL, Gillis CR, Hawthorne VM Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996 ; 313: 711 - 5.
28. Katzmarzyk PT, Mason C. Prevalence of class I, II and III obesity in Canada. CMAJ 2006 ; 174: 156 - 7.
29. Casanova C., Cote C., de Torres JP et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005 ; 171: 591 - 7.
30. Eid AA, Ionescu AA, Nixon LS et al. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001 ; 164: 1414 - 8.
31. Debigaré R., Marquis K., Côté CH et al. Catabolic/anabolic balance and muscle wasting in patients with COPD. Chest 2003 ; 124: 83 - 9.
32. Weyer C., Funahashi T., Tanaka S. et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001 ; 86: 1930 - 5.
33. Schols AM, Creutzberg EC, Buurman WA, Campfield LA, Saris WH, Wouters EF Plasma leptin is related to proinflammatory status and dietary intake in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999 ; 160: 1220 - 6.
34. Wisniacki N., Taylor W., Lye M., Wilding JP Insulin resistance and inflammatory activation in older patients with systolic and diastolic heart failure. Heart 2005 ; 91: 32 - 7.